Melanoma-induced immunosuppression and its neutralization

Seminars in Cancer Biology

Volumn 22, Issue 4, 2012, Pages 319-326

  Umansky, Viktor ^a   Sevko, Alexandra ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chronic inflammation; Immunosuppression; Melanoma; Myeloid derived suppressor cells; Tumor microenvironment

Indexed keywords

PACLITAXEL; SILDENAFIL;

CANCER GROWTH; CANCER IMMUNOLOGY; CHRONIC INFLAMMATION; DRUG MECHANISM; HUMAN; IMMUNOREGULATION; LYMPHOCYTE ACTIVATION; MELANOMA; NONHUMAN; REVIEW; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT;

ANIMALS; CHRONIC DISEASE; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INFLAMMATION; MELANOMA; MOLECULAR TARGETED THERAPY; MYELOID CELLS; SKIN NEOPLASMS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84862143053     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2012.02.003     Document Type: Review

References (114)

1. MacKie R.M., Hauschild A., Eggermont A.M. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009, 20(suppl. 6):vi1-vi7.
2. Garbe C., Peris K., Hauschild A., Saiag P., Middleton M., Spatz A., et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010, 46:270-283.
3. Cipponi A., Wieers G., van Baren N., Coulie P.G. Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?. Cancer Immunol Immunother 2011, 60:1153-1160.
4. Parmiani G., Castelli C., Santinami M., Rivoltini L. Melanoma immunology: past, present and future. Curr Opin Oncol 2007, 19:121-127.
5. Ramirez-Montagut T., Turk M.J., Wolchok J.D., Guevara-Patino J.A., Houghton A.N. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 2003, 22:3180-3187.
6. Yuan J., Adamow M., Ginsberg B.A., Rasalan T.S., Ritter E., Gallardo H.F., et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA 2011, 108:16723-16728.
7. Rosenberg S.A. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol 2011, 8:577-585.
8. Klebanoff C.A., Acquavella N., Yu Z., Restifo N.P. Therapeutic cancer vaccines: are we there yet. Immunol Rev 2011, 239:27-44.
9. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 2008, 18:11-18.
10. Rivoltini L., Canese P., Huber V., Iero M., Pilla L., Valenti R., et al. Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control. Expert Opin Biol Ther 2005, 5:463-476.
11. Ferrone S., Marincola F.M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995, 16:487-494.
12. Burke S., Lakshmikanth T., Colucci F., Carbone E. New views on natural killer cell-based immunotherapy for melanoma treatment. Trends Immunol 2010, 31:339-345.
13. Kusmartsev S., Gabrilovich D.I. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 2006, 25:323-331.
14. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005, 5:263-274.
15. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
16. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M.G., et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008, 18:349-355.
17. De Palma M., Murdoch C., Venneri M.A., Naldini L., Lewis C.E. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 2007, 28:519-524.
18. Fridlender Z.G., Sun J., Kim S., Kapoor V., Cheng G., Ling L., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: N1 versus N2 TAN. Cancer Cell 2009, 16:183-194.
19. De Santo C., Arscott R., Booth S., Karydis I., Jones M., Asher R., et al. Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol 2010, 11:1039-1046.
20. Shurin M.R., Naiditch H., Zhong H., Shurin G.V. Regulatory dendritic cells: new targets for cancer immunotherapy. Cancer Biol Ther 2011, 11:988-992.
21. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 2011, 12:715-723.
22. Rook G.A., Dalgleish A. Infection, immunoregulation, and cancer. Immunol Rev 2011, 240:141-159.
23. Cramer D.W., Finn O.J. Epidemiologic perspective on immune-surveillance in cancer. Curr Opin Immunol 2011, 23:265-271.
24. Mantovani A. Molecular pathways linking inflammation and cancer. Curr Mol Med 2010, 10:369-373.
25. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
26. Allavena P., Germano G., Marchesi F., Mantovani A. Chemokines in cancer related inflammation. Exp Cell Res 2011, 317:664-673.
27. Baniyash M. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin Cancer Biol 2006, 16:80-88.
28. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010, 59:1593-1600.
29. Tan T.T., Coussens L.M. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007, 19:209-216.
30. Navarini-Meury A.A., Conrad C. Melanoma and innate immunity - active inflammation or just erroneous attraction?: melanoma as the source of leukocyte-attracting chemokines. Semin Cancer Biol 2009, 19:84-91.
31. Nevala W.K., Vachon C.M., Leontovich A.A., Scott C.G., Thompson M.A., Markovic S.N. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res 2009, 15:1931-1939. Melanoma Study Group of the Mayo Clinic Cancer Center.
32. Tatsumi T., Kierstead L.S., Ranieri E., Gesualdo L., Schena F.P., Finke J.H., et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002, 196:619-628.
33. Mahabeleshwar G.H., Byzova T.V. Angiogenesis in melanoma. Semin Oncol 2007, 34:555-565.
34. Milella M., Felici A. Biology of metastatic renal cell carcinoma. J Cancer 2011, 2:369-373.
35. Richmond A., Yang J., Su Y. The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res 2009, 22:175-186.
36. Murakami T., Cardones A.R., Hwang S.T. Chemokine receptors and melanoma metastasis. J Dermatol Sci 2004, 36:71-78.
37. Talmadge J.E. Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact. Semin Cancer Biol 2011, 21:131-138.
38. Raman D., Baugher P.J., Thu Y.M., Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007, 256:137-165.
39. Labrousse A.L., Ntayi C., Hornebeck W., Bernard P. Stromal reaction in cutaneous melanoma. Crit Rev Oncol Hematol 2004, 49:269-275.
40. Somasundaram R., Herlyn D. Chemokines and the microenvironment in neuroectodermal tumor-host interaction. Semin Cancer Biol 2009, 19:92-96.
41. Yang J., Splittgerber R., Yull F.E., Kantrow S., Ayers G.D., Karin M., et al. Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J Clin Invest 2010, 120:2563-2574.
42. Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6:447-458.
43. Sumimoto H., Imabayashi F., Iwata T., Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006, 203:1651-1656.
44. Haluska F., Pemberton T., Ibrahim N., Kalinsky K. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. Semin Oncol 2007, 34:546-554.
45. Sawanobori Y., Ueha S., Kurachi M., Shimaoka T., Talmadge J.E., Abe J., et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008, 111:5457-5466.
46. Kato M., Takahashi M., Akhand A.A., Liu W., Dai Y., Shimizu S., et al. Transgenic mouse model for skin malignant melanoma. Oncogene 1999, 17:1885-1888.
47. Becker J.C., Houben R., Schrama D., Voigt H., Ugurel S., Reisfeld R.A. Mouse models for melanoma: a personal perspective. Exp Dermatol 2010, 19:157-164.
48. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400:468-472.
49. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 1999, 17:380-383.
50. Umansky V., Abschuetz O., Osen W., Ramacher M., Zhao F., Kato M., et al. Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. Cancer Res 2008, 68:9451-9458.
51. Houghton A., Polsky D. Focus on melanoma. Cancer Cell 2002, 2:275-278.
52. Zhao F., Falk C., Osen W., Kato M., Schadendorf D., Umansky V. Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res 2009, 15:4382-4390.
53. Palmer S.R., Erickson L.A., Ichetovkin I., Knauer D.J., Markovic S.N. Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin Proc 2011, 86:981-990.
54. Meyer C., Sevko A., Ramacher M., Bazhin A.V., Falk C.S., Osen W., et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA 2011, 108:17111-17116.
55. Apte R.N., Voronov E. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy. Immunol Rev 2008, 222:222-241.
56. Dinarello C.A. Interleukin-1beta and the autoinflammatory diseases. N Engl J Med 2009, 360:2467-2470.
57. Conti I., Rollins B.J. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 2004, 14:149-154.
58. Bonecchi R., Locati M., Mantovani A. Chemokines and cancer: a fatal attraction. Cancer Cell 2011, 19:434-435.
59. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735-6741.
60. Kimpfler S., Sevko A., Ring S., Falk C., Osen W., Frank K., et al. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J Immunol 2009, 183:6330-6337.
61. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998, 95:7556-7561.
62. Ikeda H., Old L.J., Schreiber R.D. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002, 13:95-109.
63. He Y.F., Wang X.H., Zhang G.M., Chen H.T., Zhang H., Feng Z.H. Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol Immunother 2005, 54:891-897.
64. Zaidi M.R., Merlino G. The two faces of interferon-γ in cancer. Clin Cancer Res 2011, 17:6118-6124.
65. Bronstein-Sitton N., Vaknin I., Ezernitchi A.V., Leshem B., Halabi A., Houri-Hadad Y., et al. Sustained exposure to bacterial antigen induces interferon gamma-dependent T cell receptor zeta down-regulation and impaired T cell function. Nat Immunol 2003, 4:957-964.
66. Rössner S., Voigtländer C., Wiethe C., Hänig J., Seifarth C., Lutz M.B. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur J Immunol 2005, 35:3533-3544.
67. Marigo I., Bosio E., Solito S., Mesa C., Fernandez A., Dolcetti L., et al. Tumor-induced tolerance and immune suppression depend on the C/EBPb transcription factor. Immunity 2010, 32:790-802.
68. Peranzoni E., Zilio S., Marigo I., Dolcetti L., Zanovello P., Mandruzzato S., et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010, 22:238-244.
69. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009, 182:4499-4506.
70. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003, 198:1741-1752.
71. Condamine T., Gabrilovich D.I. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011, 32:19-25.
72. Bronte V., Zanovello P. Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 2005, 5:641-654.
73. Rodríguez P.C., Ochoa A.C. T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Semin Cancer Biol 2006, 16:66-72.
74. Umansky V., Schirrmacher V. Nitric oxide-induced apoptosis in tumor cells. Adv Cancer Res 2001, 82:107-131.
75. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001, 2:907-916.
76. Nagaraj S., Schrum A.G., Cho H.I., Celis E., Gabrilovich D.I. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 2010, 184:3106-3116.
77. Molon B., Ugel S., Del Pozzo F., Soldani C., Zilio S., Avella D., et al. Chemokine nitrosylation prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 2011, 208:1949-1962.
78. Sebens Müerköster S., Werbing V., Sipos B., Debus M.A., Witt M., Grossmann M., et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 2007, 26:2759-2768.
79. Srivastava M.K., Sinha P., Clements V.K., Rodriguez P., Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010, 70:68-77.
80. + T cells. J Immunol 2009, 183:937-944.
81. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007, 25:2546-2553.
82. Poschke I., Mougiakakos D., Hansson J., Masucci G.V., Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010, 70:4335-4345.
83. Serafini P., Borrello I., Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006, 16:53-65.
84. Ezernitchi A.V., Vaknin I., Cohen-Daniel L., Levy O., Manaster E., Halabi A., et al. TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol 2006, 177:4763-4772.
85. Rodríguez P.C., Zea A.H., Culotta K.S., Zabaleta J., Ochoa J.B., Ochoa A.C. Regulation of T cell receptor CD3zeta chain expression by l-arginine. J Biol Chem 2002, 277:21123-21129.
86. Baniyash M. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 2004, 4:675-687.
87. Nakagomi H., Petersson M., Magnusson I., Juhlin C., Matsuda M., Mellstedt H., et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993, 53:5610-5612.
88. Whiteside T.L. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer. Cancer Immunol Immunother 2004, 53:865-878.
89. Ugel S., Delpozzo F., Desantis G., Papalini F., Simonato F., Sonda N., et al. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 2009, 9:470-481.
90. Mirza N., Fishman M., Fricke I., Dunn M., Neuger A.M., Frost T.J., et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006, 66:9299-9307.
91. Pan P.Y., Wang G.X., Yin B., Ozao J., Ku T., Divino C.M., et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008, 111:219-228.
92. Vincent J., Mignot G., Chalmin F., Ladoire S., Bruchard M., Chevriaux A., et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010, 70:3052-3061.
93. Suzuki E., Kapoor V., Jassar A.S., Kaiser L.R., Albelda S.M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005, 11:6713-6721.
94. Roth F., De La Fuente A.C., Vella J.L., Zoso A., Inverardi L., Serafini P Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression. Cancer Res 2012, 10.1158/0008-5472.CAN-11-2772.
95. Sinha P., Clements V.K., Fulton A.M., Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007, 67:4507-4513.
96. Fujita M., Kohanbash G., Fellows-Mayle W., Hamilton R.L., Komohara Y., Decker S.A., et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 2011, 71:2664-2674.
97. De Santo C., Serafini P., Marigo I., Dolcetti L., Bolla M., Del Soldato P., et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci USA 2005, 102:4185-4190.
98. Capuano G., Rigamonti N., Grioni M., Freschi M., Bellone M. Modulators of arginine metabolism support cancer immunosurveillance. BMC Immunol 2009, 10:1.
99. Ghofrani H.A., Osterloh I.H., Grimminger F. Sildenafil from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006, 5:689-702.
100. Serafini P., Meckel K., Kelso M., Noonan K., Califano J., Koch W., et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006, 203:2691-2702.
101. Serafini P., Mgebroff S., Noonan K., Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008, 68:5439-5449.
102. Cheng P., Corzo C.A., Luetteke N., Yu B., Nagaraj S., Bui M.M., et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008, 205:2235-2249.
103. Sinha P., Okoro C., Foell D., Freeze H.H., Ostrand-Rosenberg S., Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 2008, 181:4666-4675.
104. Tartour E., Pere H., Maillere B., Terme M., Merillon N., Taieb J., et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011, 30:83-95.
105. De Boniface J., Poschke I., Mao Y., Kiessling R. Tumor-dependent down-regulation of the ζ-chain in T-cells is detectable in early breast cancer and correlates with immune cell function. Int J Cancer 2011, 10.1002/ijc.26355.
106. Laties A., Zrenner E. Viagra (sildenafil citrate) and ophthalmology. Prog Retin Eye Res 2002, 21:485-506.
107. Zitvogel L., Kepp O., Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011, 8:151-160.
108. Locher C., Conforti R., Aymeric L., Ma Y., Yamazaki T., Rusakiewicz S., et al. Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci 2010, 1209:99-108.
109. Kaneno R., Shurin G.V., Kaneno F.M., Naiditch H., Luo J., Shurin M.R. Chemotherapeutic agents in low non-cytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol (Dordr) 2011, 34:97-106.
110. Kaneno R., Shurin G.V., Tourkova I.L., Shurin M.R. Chemomodulation of human dendritic cell function by anti-neoplastic agents in low non-cytotoxic concentrations. J Transl Med 2009, 7:58.
111. Shurin G.V., Tourkova I.L., Kaneno R., Shurin M.R. Chemotherapeutic agents in non-cytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 2009, 183:137-144.
112. Shurin G.V., Tourkova I.L., Shurin M.R. Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells. J Immunother 2008, 31:491-499.
113. Zhong H., Han B., Tourkova I.L., Lokshin A., Rosenbloom A., Shurin M.R., et al. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res 2007, 13:5455-5462.
114. Michels T., Shurin G.V., Naiditch H., Umansky V., Sevko A., Shurin M.R. Paclitaxel promotes differentiation of myeloid derived suppressor cells into dendritic cells in vitro in the TLR4-independent manner. J Immunotoxicol 2012, 10.3109/1547691X.2011.642418.